The evidence pile for psilocybin’s efficacy in treating depression is growing with new data demonstrating 79% remission rates after two doses. Meanwhile, early trials hint at MEAI’s efficacy in treating obesity, ketamine studies suggest a single dose is effective in treating anxiety and discussions arise about psychedelic use and its capacity to birth new environmentalists.
No comment yet, add your voice below!